Centre for Quality Management of Medicine, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Department of Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA, Selangor, Malaysia.
PLoS One. 2023 Sep 28;18(9):e0290883. doi: 10.1371/journal.pone.0290883. eCollection 2023.
Cardiovascular disease (CVD) is a leading cause of death and disability worldwide, imposing a significant burden on patients and healthcare systems. The role of pharmacists in reducing cardiovascular disease (CVD) is pivotal as they play an essential part in the healthcare team, particularly in medication management and patient education. Pharmacists are well-positioned to contribute to the prevention and control of CVD through various roles, including medication management and patient education. This study aims to investigate the current involvement of community pharmacists in Malaysia, specifically in cardiovascular diseases-related health promotion activities and dyslipidemia management, including their perceived barriers.
This cross-sectional survey was conducted among community pharmacists in all 14 states of Malaysia between November 2021 and July 2022. The self-administered survey was shared to relevant groups through various social media platforms.
A total of 312 community pharmacists were involved in the survey. Majority of the respondents were females (66%), with a mean age (SD) of 32.9 (8.4) years. Most of the respondents showed satisfactory practice for patient counselling, but improvements are needed particularly in risk assessment and collaborative care aspect. Most of them expressed their interest for dyslipidemia management training (89.4%). Lack of access to medical records (71.2%) and lack of CVD-related educational materials (70.8%) were the two main perceived barriers identified.
Community pharmacists in Malaysia provide a satisfactory role in the provision of cardiovascular disease-related health promotion activities, especially in providing patient counselling. Strengthening collaborative care is essential for providing comprehensive and patient-centered intervention in dyslipidemia management. This requires ongoing efforts to address and overcome existing barriers for effective teamwork and coordination among healthcare professionals.
心血管疾病(CVD)是全球范围内导致死亡和残疾的主要原因,给患者和医疗保健系统带来了巨大的负担。药剂师在减少心血管疾病(CVD)方面发挥着关键作用,因为他们在医疗团队中扮演着重要角色,特别是在药物管理和患者教育方面。药剂师通过各种角色,包括药物管理和患者教育,有能力为 CVD 的预防和控制做出贡献。本研究旨在调查马来西亚社区药剂师目前在心血管疾病相关健康促进活动和血脂异常管理方面的参与情况,包括他们认为的障碍。
本横断面调查于 2021 年 11 月至 2022 年 7 月在马来西亚所有 14 个州的社区药剂师中进行。通过各种社交媒体平台向相关群体分享了自我管理的调查。
共有 312 名社区药剂师参与了调查。大多数受访者为女性(66%),平均年龄(SD)为 32.9(8.4)岁。大多数受访者在患者咨询方面表现出满意的实践,但在风险评估和协作护理方面需要改进。他们大多数人对血脂异常管理培训表示感兴趣(89.4%)。缺乏访问医疗记录(71.2%)和缺乏 CVD 相关教育材料(70.8%)是确定的两个主要障碍。
马来西亚的社区药剂师在提供心血管疾病相关健康促进活动方面发挥了令人满意的作用,特别是在提供患者咨询方面。加强协作护理对于提供全面和以患者为中心的血脂异常管理干预至关重要。这需要持续努力解决和克服现有的障碍,以实现医疗保健专业人员之间的有效团队合作和协调。